Nuveen’s Enfusion, Inc. ENFN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-104,821
| Closed | -$1.16M | – | 3323 |
|
|
2025
Q2 | $1.16M | Hold |
104,821
| – | – | ﹤0.01% | 2532 |
|
|
2025
Q1 | $1.17M | Buy |
104,821
+8,997
| +9% | +$99.5K | ﹤0.01% | 2575 |
|
|
2024
Q4 | $987K | Hold |
95,824
| – | – | ﹤0.01% | 2718 |
|
|
2024
Q3 | $909K | Hold |
95,824
| – | – | ﹤0.01% | 2805 |
|
|
2024
Q2 | $816K | Buy |
95,824
+14,575
| +18% | +$133K | ﹤0.01% | 2817 |
|
|
2024
Q1 | $752K | Hold |
81,249
| – | – | ﹤0.01% | 2818 |
|
|
2023
Q4 | $788K | Buy |
81,249
+536
| +0.7% | +$5.01K | ﹤0.01% | 2832 |
|
|
2023
Q3 | $724K | Buy |
80,713
+16,453
| +26% | +$156K | ﹤0.01% | 2706 |
|
|
2023
Q2 | $721K | Hold |
64,260
| – | – | ﹤0.01% | 2804 |
|
|
2023
Q1 | $675K | Sell |
64,260
-536
| -0.8% | -$5.91K | ﹤0.01% | 2733 |
|
|
2022
Q4 | $626K | Sell |
64,796
-4,359
| -6% | -$49.1K | ﹤0.01% | 2822 |
|
|
2022
Q3 | $854K | Buy |
69,155
+1,395
| +2% | +$17K | ﹤0.01% | 2813 |
|
|
2022
Q2 | $692K | Buy |
67,760
+17,642
| +35% | +$195K | ﹤0.01% | 2933 |
|
|
2022
Q1 | $638K | Buy |
50,118
+16,370
| +49% | +$250K | ﹤0.01% | 2944 |
|
|
2021
Q4 | $707K | Buy |
+33,748
| New | +$682K | ﹤0.01% | 2973 |
|
Nuveen's ENFN Position: Q3 2025 in Review
Nuveen sold out of Enfusion, Inc. (ENFN) in Q3 2025, closing a stake of 104,821 shares — an estimated $1.16M sold.
Nuveen first reported a position in ENFN in Q4 2021 and held it in 15 quarters. The position peaked at $1.17M in Q1 2025. 0 funds tracked by Wall St. Rank hold ENFN as of Q3 2025.
- Nuveen reported no remaining Enfusion, Inc. position as of Q3 2025 after selling out during the quarter.
- Nuveen sold 104,821 Enfusion, Inc. shares in Q3 2025, an estimated $1.16M.
- Nuveen first reported a position in Enfusion, Inc. in Q4 2021 and held it in 15 quarters.
- Nuveen's Enfusion, Inc. position peaked at $1.17M in Q1 2025.
- 0 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q3 2025.
Based on Nuveen's 13F filing for Q3 2025, filed 12 Nov 2025.